Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

0.5085 -0.0153 (-2.92%)
Streaming Delayed Price Updated: 12:42 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SciSparc Ltd. - Ordinary Shares

News headline image
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery
From SciSparc Ltd
Via GlobeNewswire
News headline image
News Alert: Synergy (NASDAQ: SNYR) Expands FOCUSfactor® Across Southeastern US – More Stocks Inside
Via AB Newswire
News headline image
SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces 1-for-21 Reverse Share Split
Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held 
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces Publication of Japanese Patent Application
From SciSparc Ltd
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.